secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZEVRA THERAPEUTICS, INC. (ZVRA)
CIK:        0001434647
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0001437749-24-026397
Event type: earnings
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zevra Q2 revenue falls to $4.4M, net loss $19.9M; FDA decision on arimoclomol by Sept 21
--------------------------------------------------------------------------------

- Net revenue $4.4M vs $8.5M YoY; net loss $19.9M ($0.48/share) vs $2.6M ($0.08/share) in Q2 2023.
- FDA advisory committee voted arimoclomol effective for NPC; PDUFA target action date Sept 21, 2024.
- Pro-forma cash $113.8M after $64.5M net from August public offering; cash runway into Q1 2027.
- OLPRUVA added 9 new patient enrollments in Q2; reimbursement coverage expanded to 75% of covered lives.
- Refinanced debt with $100M credit facility from Perceptive Advisors and HCR; initial draw $60M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434647/000143774924026397/0001437749-24-026397-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434647/000143774924026397/zvra20240520_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-026397

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer